Four UK antidepressants suppliers accused of anti-competitive conduct

The UK’s Competition and Markets Authority (CMA) has accused competitors King and Auden Mckenzie of sharing out between them the supply of nortriptyline to a large pharmaceutical wholesaler.

The CMA has provisionally found that, in 2014, the 2 companies agreed Auden Mckenzie (owned by India’s Intas) would supply only 10mg nortriptyline tablets and King would supply only 25mg nortriptyline tablets, as well as agreeing to fix the quantities and the prices of supply.

The CMA has also accused the companies King, Alissa and Lexon of exchanging commercially sensitive information, including information about prices, volumes and entry plans, to try to keep nortriptyline prices high.